<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=141617"><dc:title>High-shear wet granulation of SMEDDS based on mesoporous carriers for improved carvedilol solubility</dc:title><dc:creator>Kovačević,	Mila	(Avtor)
	</dc:creator><dc:creator>German Ilić,	Ilija	(Avtor)
	</dc:creator><dc:creator>Bolko Seljak,	Katarina	(Avtor)
	</dc:creator><dc:creator>Zvonar Pobirk,	Alenka	(Avtor)
	</dc:creator><dc:subject>SMEDDS</dc:subject><dc:subject>mesoporous carriers</dc:subject><dc:subject>wet granulation</dc:subject><dc:subject>high-shear granulator</dc:subject><dc:description>Mesoporous carriers are a convenient choice for the solidification of self-microemulsifying drug delivery systems (SMEDDS) designed to improve the solubility of poorly water-soluble drugs. They are known for high liquid load capacity and the ability to maintain characteristics of dry, free-flowing powders. Therefore, five different mesoporous carriers were used for the preparation of carvedilol-loaded SMEDDS granules by wet granulation methods—in paten (manually) and using a high-shear (HS) granulator. Granules with the highest SMEDDS content (63% and 66% of total granules mass, respectively) and suitable flow properties were obtained by Syloid$^®$ 244FP and Neusilin$^®$ US2. SMEDDS loaded granules produced by HS granulation showed superior flow characteristics compared to those obtained manually. All SMEDDS granules exhibited fast in vitro release, with 93% of carvedilol releasing from Syloid$^®$ 244FP-based granules in 5 min. Upon compaction into self-microemulsifying tablets, suitable tablet hardness and very fast disintegration time were achieved, thus producing orodispersible tablets. The compaction slightly slowed down the carvedilol release rate; nevertheless, upon 1 h (at pH 1.2) or 4 h (at pH 6.8) of in vitro dissolution testing, the amount of released drug was comparable with granules, confirming the suitability of orodispersible tablets for the production of the SMEDDS loaded single unit oral dosage form.</dc:description><dc:date>2022</dc:date><dc:date>2022-10-03 08:49:01</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>141617</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
